Answers are grounded in this paper and cite their sources.
Introduction. Intrahepatic cholestasis of pregnancy (ICP) is a reversible degenerative liver disorder caused by the increased sensitivity of hepatocytes and biliary ducts to sex hormones, as well as genetically determined enzymopathies. This condition poses a potential risk to the fetus. Blood bile acids are the most sensitive diagnostic marker for ICP. In enzymatic quantification total bile acids concentration, interference with ursodeoxycholic acid (UDCA) preparations is possible. Therefore, it is of interest to evaluate the feasibility of using a diagnostic kit for measuring (using latex immunoturbidimetric assay) the concentration of the main bile component, cholic acid-glycine conjugate (cholyglycine), for ICP diagnosis. Aim. To assess the feasibility of using cholyglycine concentration as a marker for ICP diagnosis and monitoring. Materials and methods. The study included 40 patients diagnosed with ICP (the main group) and 28 non-pregnant healthy patients (the control group). Six patients receiving therapy with UDCA were followed-up. Cholyglycine, total bile acids, alanine aminotransferase (ALT), aspartate aminotransferase (AST), as well as total and direct bilirubin concentrations were measured in both groups. Results. Patients with ICP had elevated cholyglycine compared to controls. An increase in total bile acids, ALT, and AST values were observed, along with a characteristic decrease in the De Ritis ratio. A dynamic relationship between cholyglycine and total bile acid concentrations was established. In six patients with ICP who received ursodeoxycholic acid for one or two weeks after hospitalization, the cholyglycine concentration showed a more pronounced decrease or stabilized during treatment. Simultaneously, an increase in the total bile acids concentration was observed in some cases, likely due to interference with UDCA preparations. Conclusion. The feasibility of using a kit for measurement (with latex immunoturbidimetric method) of the cholyglycine concentration during in vitro diagnostics of ICP and the assessment of the effectiveness of treatment of this pathology during UDCA therapy was demonstrated.
No takes yet. Share an insight, caveat, or question.
Demidova et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: